ACM
KRYS icon

ADAR1 Capital Management’s Krystal Biotech KRYS Stock Holding History

ADAR1 Capital Management’s Portfolio KRYS Stock Details KRYS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$6.1M Sell
16,420
-3,594
-18% -$1.07M 0.28% 82
2026
Q1 		$5.17M Hold
20,014
– – 0.3% 72
2025
Q4 		$4.93M Buy
20,014
+1,491
+8% +$314K 0.36% 61
2025
Q3 		$3.27M Buy
+18,523
New +$2.77M 0.31% 59
2024
Q4 		– Sell
-100
Closed -$18.2K – 261
2024
Q3 		$18.2K Buy
+100
New +$19.3K ﹤0.01% 243
2024
Q2 		– Sell
-300
Closed -$53.4K – 298
2024
Q1 		$53.4K Buy
+300
New +$41.7K 0.01% 175

Other funds holding KRYS

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
SCM
Soleus Capital Management Greenwich, Connecticut $2.9B AUM 169.69% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

ADAR1 Capital Management's KRYS Position: Q2 2026 in Review

ADAR1 Capital Management reduced its Krystal Biotech (KRYS) stake by 18% in Q2 2026, selling an estimated $1.07M and leaving 16,420 shares worth $6.1M. The position accounts for 0.28% of the portfolio, ranked #82.

ADAR1 Capital Management first reported a position in KRYS in Q1 2024 and has held it in 6 quarters since. 423 funds tracked by Wall St. Rank hold KRYS as of Q2 2026.

  • ADAR1 Capital Management held 16,420 shares of Krystal Biotech worth $6.1M as of Q2 2026.
  • ADAR1 Capital Management sold 3,594 Krystal Biotech shares in Q2 2026, an estimated $1.07M.
  • Krystal Biotech made up 0.28% of ADAR1 Capital Management's portfolio in Q2 2026, its #82 holding.
  • ADAR1 Capital Management first reported a position in Krystal Biotech in Q1 2024 and has held it in 6 quarters since.
  • 423 funds tracked by Wall St. Rank held Krystal Biotech as of Q2 2026.

Based on ADAR1 Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.